Veracyte Receivables

Veracyte (VCYT) currently reports a receivables of $50M as of March 2026. That compares with $54M in the prior-year period — down 6.8% year over year. Use the charts on this page to explore Veracyte's receivables history and peer comparisons.

Veracyte's receivables decreased from $54M to $50M — a 6.8% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Veracyte reported $50M in receivables as of March 2026. That compares with $54M in the prior-year period — down 6.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $50M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Veracyte, and consider following VCYT for alerts when major investors trade the stock.

Veracyte is classified in the Healthcare sector. On receivables, it currently shows $50M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing VCYT with unrelated industries.